Popular Articles

Ardea Biosciences Initiates Phase 2b Clinical Trial Of RDEA594, Lead Product Candidate For The Treatment Of Gout
Ardea Biosciences, Inc. (Nasdaq:RDEA) today announced that it has initiated a Phase 2b clinical trial of RDEA594, its lead product candidate in development for the management of hyperuricemia and gout. The Company also announced the selection of RDEA684, a next-generation URAT1 inhibitor, as a development candidate for the same indication.

Early Mental Illness May Be Revealed By MRI Mapping Of Brain
John Csernansky wants to take your measurements. Not the circumference of your chest, waist and hips. No, this doctor wants to stretch a tape measure around your hippocampus, thalamus and prefrontal cortex.
News of the day
Public Health

Recession Prompting Increase In Number Of People With HIV Seeking Public Services In California

The Los Angeles Times on Sunday examined how the recession is impacting people living with HIV in California. Brad Hare, medical director of University of California-San Francisco"s Positive Health Program at San Francisco General Hospital, said that people living with HIV who have lost their jobs and private health insurance are turning to public and nonprofit clinics for the first time and are responsible for a 12% increase this year in the clinic"s overall patient visits. He added that many of the patients he sees have gone months without receiving medical care. In addition, at the Los Angeles Gay and Lesbian Center, which also provides HIV treatment, the number of new patients has doubled over the last year, Thomas Soule, a spokesperson for the center, said. The Times also profiled a client of the center (Lin, Los Angeles Times, 5/31). This information was reprinted from dailyreports.kff.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily U.S. HIV/AIDS Report, search the archives and sign up for email delivery at dailyreports.kff.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):